Pharmaceutical Reimbursement Strategies: Maximizing Revenue Potential in Europe, US and Japan

Introduction:

In light of an R&D productivity crisis and an impending wave of blockbuster patent expiries, it is becoming increasingly important for pharmaceutical companies to achieve the optimum reimbursement status for a drug during its entire lifecycle. This Analysis examines the opportunities available to companies to maximize the reimbursement potential for pharmaceutical products. 

Scope:

* Analysis of key regulatory developments in pricing and reimbursement in seven major markets (France, Germany, Italy, Japan, Spain, the UK and the US) 

* Case-studies detailing the initiatives adopted by companies to address reimbursement issues 

* Analysis of reimbursement trends, together with the identification and examination of deficiencies within current industry practices 

* Analysis of pharmaceutical companies’ use of external organizations in supporting reimbursement objectives 

Report Highlights:

Forty-nine per cent of surveyed industry executives stated that their organizations are failing to commit adequate time and resources to reimbursement issues. 

Companies must integrate pharmacoeconomics more effectively to maximize reimbursement potential, driven by increased use of economic evaluation by payors in reimbursement decision-making. Adopting a decentralized approach to the distribution of pharmacoeconomic expertise throughout organizations is one strategy for improving performance 

Pharmaceutical companies must address reimbursement earlier in the product lifecycle to steer product development and enable efficient capital and resource allocation. 

Reasons to Purchase:

* Develop industry best practice by accessing analysis on the role of pharmacoeconomics in reimbursement throughout product development 

* Enhance product value communication by understanding the relative importance of various factors on reimbursement decision-makers’ thinking 

* Create forward-focused strategies by analyzing current and future pricing and reimbursement developments in the seven major markets 

Publisher: Datamonitor Drug Discovery Reports 

To order go to this URL: http://www.bioportfolio.com/cgi-bin/acatalog/Datamonitor_Drug_Discovery.html#a124